Unlocking the Value of Precision Medicine
WellDyne clinical leaders Nick Page and Patty Taddei-Allen are slated to lead a forward-looking educational session at AMCP Nexus 2021, exploring how the power of genetics is changing the healthcare landscape and impacting pharmacists, PBMs and patients. As one of the most exciting, emerging fields in healthcare, precision medicine helps prescribers make the best choice of drug and dosage for each individual – the first time – minimizing side effects and costly trial-and-error.
Unlocking the Value of Precision Medicine
Presented by Nick Page, Chief Clinical and Strategy Officer and Patty Taddei-Allen, VP, Clinical Programs and Services
October 21, 2021, 10-11:15 am
AMCP Nexus, Denver, CO
As they explore this rapidly emerging field, Nick and Patty will:
- Examine how evidence-based, clinical decision support can be leveraged in the new era of pharmacogenomic testing.
- Discuss key elements of plan design to maximize the value of precision medicine.
- Describe the potential impact of pharmacogenomics and precision medicine on total healthcare costs.
AMCP Nexus 2021 is in-person in Denver this year. Learn more at Igniting Action | Together, AMCP Nexus 2021.
